ABT · News · 20260819N
Product Launch and Transition
ABBOTT LABORATORIES · 2026-08-19 · Importance 31 · Surprise 42 · In source text
MiniMed Group commercially shipped the MiniMed Flex insulin pump in the United States with Abbott Laboratories’ Instinct continuous glucose sensor. The app-controlled system pairs an insulin pump with Abbott’s smallest sensor, which supports up to 15 days of wear. The integration is positioned to provide a more discreet, hands-free diabetes-management option and strengthen MiniMed’s competitive position in the insulin-pump market.
Key facts
- Abbott is launching next-generation products including the Volt PFA catheter and Libre Duo as part of its medical devices pipeline extending into 2029 and beyond. source
- The commercial launch of MiniMed's app-controlled MiniMed Flex insulin pump integrates Abbott’s Instinct continuous glucose sensor and has drawn investor attention, with an estimated company undervaluation mentioned at 5.4% in one article. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott is launching next-generation products including the Volt PFA catheter and Libre Duo as part of its medical devices pipeline… |
| revenue | positive | probable | — | The commercial launch of MiniMed's app-controlled MiniMed Flex insulin pump integrates Abbott’s Instinct continuous glucose sensor and has… |